See more : Braveheart Resources Inc. (2ZR.F) Income Statement Analysis – Financial Results
Complete financial analysis of Bolt Biotherapeutics, Inc. (BOLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bolt Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- KING SHING (7732.TWO) Income Statement Analysis – Financial Results
- Core Corporation (2359.T) Income Statement Analysis – Financial Results
- Sandoz Group AG (SDZNY) Income Statement Analysis – Financial Results
- Huntington Bancshares Incorporated (HBANO) Income Statement Analysis – Financial Results
- Avaya Holdings Corp. (AVYA) Income Statement Analysis – Financial Results
Bolt Biotherapeutics, Inc. (BOLT)
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 7.88M | 5.73M | 1.26M | 231.00K | 215.00K | 0.00 |
| Cost of Revenue | 1.88M | 4.89M | 3.67M | 40.36M | 26.00M | 302.00K |
| Gross Profit | 5.99M | 838.00K | -2.41M | -40.13M | -25.79M | -302.00K |
| Gross Profit Ratio | 76.08% | 14.63% | -191.43% | -17,370.56% | -11,993.95% | 0.00% |
| Research & Development | 61.54M | 73.12M | 75.66M | 40.36M | 26.00M | 9.42M |
| General & Administrative | 22.53M | 22.93M | 18.39M | 9.06M | 5.18M | 2.21M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.53M | 22.93M | 18.39M | 9.06M | 5.18M | 2.21M |
| Other Expenses | 0.00 | 0.00 | -6.08M | -11.75M | -42.00K | -153.00K |
| Operating Expenses | 84.07M | 96.05M | 94.05M | 49.41M | 31.18M | 11.63M |
| Cost & Expenses | 84.07M | 96.05M | 94.05M | 49.41M | 31.18M | 11.63M |
| Interest Income | 7.00M | 2.22M | 281.00K | 199.00K | 524.00K | 193.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.85M | 4.89M | 3.67M | 2.50M | 1.33M | 302.00K |
| EBITDA | -74.34M | -88.66M | -91.60M | -48.57M | -30.63M | -11.33M |
| EBITDA Ratio | -943.91% | -1,547.48% | -6,786.59% | -15,941.99% | -14,228.84% | 0.00% |
| Operating Income | -76.20M | -90.32M | -92.79M | -49.18M | -30.97M | -11.63M |
| Operating Income Ratio | -967.45% | -1,576.56% | -7,364.13% | -21,290.91% | -14,404.19% | 0.00% |
| Total Other Income/Expenses | 7.00M | 2.22M | -5.80M | -11.55M | 482.00K | 40.00K |
| Income Before Tax | -69.20M | -88.10M | -98.59M | -60.73M | -30.49M | -11.59M |
| Income Before Tax Ratio | -878.58% | -1,537.76% | -7,824.68% | -26,289.18% | -14,180.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.22M | 5.80M | 11.55M | -482.00K | 40.00K |
| Net Income | -69.20M | -85.88M | -104.39M | -72.27M | -30.01M | -11.59M |
| Net Income Ratio | -878.58% | -1,498.95% | -8,285.24% | -31,287.45% | -13,955.81% | 0.00% |
| EPS | -1.83 | -2.30 | -2.79 | -1.99 | -0.85 | -1.23 |
| EPS Diluted | -1.83 | -2.30 | -2.79 | -1.99 | -0.85 | -1.23 |
| Weighted Avg Shares Out | 37.81M | 37.36M | 37.40M | 36.25M | 35.10M | 9.42M |
| Weighted Avg Shares Out (Dil) | 37.81M | 37.36M | 37.40M | 36.25M | 35.10M | 9.42M |
Investors Encouraged To Join In The Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b)...
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Bolt Biotherapeutics, Inc. to Contact the Firm Today!
NEW YORK CITY, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT)...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ:BOLT) and certain officers. The class action, filed in the United...
Investors Can Take The Lead In The Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit With The Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ: BOLT ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of...
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, both dates inclusive (the...
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , Aug. 14, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ: BOLT) for violations of §§10(b) and 20(a)...
BOLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Bolt Biotherapeutics, Inc. Shareholders to Actively Participate in Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / August 14, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT)...
The Schall Law Firm Invites Investors To Lead The Securities Fraud Lawsuit Against Bolt Biotherapeutics Inc
LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b)...
Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2024, and provided a...
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. (“Bolt” or “the Company”) (NASDAQ:...
Source: https://incomestatements.info
Category: Stock Reports